AssetMark’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$470 Sell
25
-15
-38% -$303 ﹤0.01% 3425
2026
Q2
$874 Hold
40
– – ﹤0.01% 3177
2026
Q1
$934 Hold
40
– – ﹤0.01% 3053
2025
Q4
$840 Hold
40
– – ﹤0.01% 2984
2025
Q3
$615 Buy
+40
New +$524 ﹤0.01% 2896
2024
Q1
– Sell
-10
Closed -$216 – 2101
2023
Q4
$216 Buy
+10
New +$154 ﹤0.01% 1755

Other funds holding SNDX

AssetMark's SNDX Position: Q3 2026 in Review

AssetMark reduced its Syndax Pharmaceuticals (SNDX) stake by 38% in Q3 2026, selling an estimated $303 and leaving 25 shares worth $470. The position accounts for ﹤0.01% of the portfolio, ranked #3425.

AssetMark first reported a position in SNDX in Q4 2023 and has held it in 6 quarters since. The position peaked at $934 in Q1 2026. 166 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

  • AssetMark held 25 shares of Syndax Pharmaceuticals worth $470 as of Q3 2026.
  • AssetMark sold 15 Syndax Pharmaceuticals shares in Q3 2026, an estimated $303.
  • Syndax Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3425 holding.
  • AssetMark first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
  • AssetMark's Syndax Pharmaceuticals position peaked at $934 in Q1 2026.
  • 166 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.